Form 10-Q Compass Therapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- S&P 500, Nasdaq set for higher open as SK Hynix lifts chips; Fed in focus
- SK Hynix shares surge after Q3 profit beats expectations
- Oil up 1% as Saudi Arabian refinery attack reignites supply concerns
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- S&P Global explores potential separation of Capital IQ business
- Wall Street ends higher on revived AI momentum
- Nebius Group shares jump after France data center funding
- GE Vernova Inc. (GEV) Tops Q3 EPS by 81c, Beats on Revenue; Offers FY26 Revenue Guidance
- Seagate Technology (STX) Tops Q1 EPS by 29c, Offers Guidance
Compass Therapeutics (CMPX) PT Lowered to $7 at Jefferies
May 13, 2024 1:21 PM EDTJefferies analyst Maury Raycroft lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $7.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "CMPX updated pivotal BTC ph.II/III data guidance to 1Q25 (vs YE24), which we think is incremental given that enrollment... More



